Skip to main content

Treatment Clinical Trials for Advanced Carcinoma Of Unknown Primary

Review the advanced carcinoma of unknown primary treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer after Previous Treatment
Status: Active
Location: 194 locations
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Status: Active
Location: 14 locations
Alternating Chemoimmunotherapy and Immunotherapy Treatment Plans for the Treatment of Stage IV Lung Cancer or Head and Neck Cancers, The ATATcH Study
Status: Active
Location: 11 locations
A Study Comparing Personalized Radiation Therapy with Standard Radiation Therapy in People With HPV-Positive Throat Cancer
Status: Active
Location: 9 locations
Radiation Therapy and Chemotherapy De-escalation Prior to Neck Dissection Surgery for the Treatment of Laryngeal, Hypopharyngeal, or p16-Negative Oropharyngeal and Unknown Primary Head and Neck Squamous Cell Cancers
Status: Active
Location: 7 locations
Evaluating Residual Circulating Tumor DNA Levels After Surgery for Directing Adjuvant Treatment in Patients with HPV-Mediated Oropharynx Cancer, SAVAL Trial
Status: Active
Location: 5 locations
Risk-Directed Postoperative Radiation Therapy and Cisplatin for the Treatment of Stage I-II HPV-Related Oropharynx Squamous Cell Carcinoma, The Minimalist Trial-2 (MINT-2)
Status: Active
Location: 4 locations
Toripalimab in Combination with Cisplatin and Docetaxel for the Treatment of Locally Advanced Stage III or Non-metastatic Stage IV Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Status: Active
Location: 3 locations
Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Status: Active
Location: 2 locations
Personalized Treatment with Surgery, Radiation and/or Chemotherapy for Patients with Stage I-II HPV-related Squamous Cell Carcinoma of the Oropharynx
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Studying Two Dosing Schedules of Fluorouracil for the Treatment of Head and Neck Cancer in Patients who Received a Platinum Agent and PD-1 Inhibitor for Recurrent or Metastatic Disease, FROST Trial
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Decitabine in Combination with Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Zanzalintinib with Pembrolizumab and Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
TMV Vaccine Therapy alone and with Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Location: 2 locations
Mass-Based Response Testing to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Appendix and Colorectal Cancer in Patients with Peritoneal Metastasis
Status: Active
Location: Yale University, New Haven, Connecticut
Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Using Blood Tests and Clinical Features for the Risk-Adapted Adjuvant Treatment of HPV-Positive Oropharyngeal Cancer, ReACT 2.0 Trial
Status: Temporarily Closed to Accrual
Location: 2 locations